Placebo for dapagliflozin film-coated tablets 10 mg

DRUG2 trials

Sponsors

Oslo University Hospital HF, Universitair Medisch Centrum Groningen

Conditions

Combined endpoint of all-cause mortalityHeart transplantKidney failureand hospitalization for heart failure in the overall study populationkidney failure

Phase 3

DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients

Active, not recruitingCTIS2023-506486-60-01

Oslo University Hospital HFHeart transplant, Kidney failure

Start: 2022-04-26Target: 270Updated: 2025-04-08

Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease

RecruitingCTIS2023-508389-13-00

Universitair Medisch Centrum Groningenand hospitalization for heart failure in the overall study population, Combined endpoint of all-cause mortality, kidney failure

Start: 2022-11-08Target: 1560Updated: 2025-10-03